Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants with symptomatic anemia associated with CKD~* Participants with renal anemia who are not treated with an ESA:~* Anemia was defined as hemoglobin (Hb) concentration less than (\<) 11.0 grams per deciliter (g/dL) (mean of 2 screening values with at least one day and a maximum of 2 weeks between measurements) with clinical indication for ESA treatment~* Participants with renal anemia who are on maintenance ESA therapy:~* If on dialysis: regular long-term hemodialysis or peritoneal dialysis therapy with the same mode of dialysis for at least 3 months before screening~* Hb concentration between 10 and 12 g/dL (mean of 2 screening values with at least one day and a maximum of 2 weeks between measurements)~* Participants with adequate iron status defined as: serum ferritin above or equal to 100 micrograms per liter or transferrin saturation above or equal to 20 percent~Exclusion Criteria:~* Contraindications to ESA treatment: uncontrolled hypertension, hypersensitivity to the active substance or any of the excipients, any other contraindication to ESA therapy~* Conditions known to cause inadequate response to ESA treatment or anemia other than symptomatic anemia associated with CKD:~* History of hemoglobinopathy~* Anemia due to hemolysis~* Pure red cell aplasia~* High likelihood of early withdrawal (for example, within 1 year) or interruption of the study~* Pregnancy or breast-feeding~* Women of childbearing potential without effective contraception~* Administration of another investigational drug within 1 month before screening or planned during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erythropoiesis Stimulating Agents (Type: ACTIVE_COMPARATOR): Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
- Methoxy Polyethylene Glycol-Epoetin Beta (Type: EXPERIMENTAL): Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.

Based on this trial design, predict the completion outcome and termination type (if applicable).